Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2021-11-10
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 200000 NOK
Award criteria: Lowest price

Technical requirements: The Norwegian Hospital Procurement Trust (Norwegian: Sykehusinnkjøp HF), the Pharmaceutical Division is collecting tenders for pharmaceuticals that are used by the Norwegian health trusts. The Pharmaceutical Division (Norwegian abbreviation: LIS) has previously published and held an open tender contest for non-parenteral special pharmaceutical preparations ('2201b non-parenteral special pharmaceutical preparations').
The contest was for the delivery of active ingredients in accordance with the tender documentation, annex 3 price sheet. Following the implementation of the tender contest, tenders have been made for Vimpat tablets and mixture (ATC code N03AX18). We received no other tenders for the relevant ATC code included in the tender contest. Based on this, the Pharmaceutical Division (Norwegian abbreviation: LIS) intends to enter into contracts between the regional health trusts (the Contracting Authorities) and UCB Pharma AS (the Supplier) as an supplementary agreement to LIS 2201b. I.e., the scope and length of the agreement shall follow the mentioned procurement (including access to extensions and terminations), without a new contest being held for this ingredient.
The Norwegian Hospital Procurement Trust (Norwegian: Sykehusinnkjøp HF), the Pharmaceutical Division is collecting tenders for pharmaceuticals that are used by the Norwegian health trusts. The Pharmaceutical Division (Norwegian abbreviation: LIS) has previously published and held an open tender contest for non-parenteral special pharmaceutical preparations ('LIS 2201b non-parenteral special pharmaceutical preparations').
The contest was for the delivery of active ingredients in accordance with the tender documentation, annex 3 price sheet. Following the implementation of the tender contest, tenders have been made for Vimpat tablets and mixture (ATC code N03AX18). We received no other tenders for the relevant ATC code included in the tender contest. Based on this, the Pharmaceutical Division (Norwegian abbreviation: LIS) intends to enter into contracts between the regional health trusts (the Contracting Authorities) and UCB Pharma AS (the Supplier) as an supplementary agreement to LIS 2201b. I.e., the scope and length of the agreement shall follow the mentioned procurement (including access to extensions and terminations), without a new contest being held for this ingredient.
The health companies that are under the regional health trusts have an option to enter into the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region. LIS has explored the market situation and is of the opinion that it is impossible to carry out a new invitation to tender, or that a supplier other than UCB Pharma AS can deliver the product in the impending contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. LIS therefore believes that there are grounds to carry out the procurement without a tender contest. Cf. the Public Procurement Regulations §13-4, letter b, no. 3. LIS requests that those who have objections to the intended contract award submit feedback before the waiting period expires on 14.11.2021. If no objections are received, contracts will be signed after the waiting period has expired
The Norwegian Hospital Procurement Trust (Norwegian: Sykehusinnkjøp HF), the Pharmaceutical Division is collecting tenders for pharmaceuticals that are used by the Norwegian health trusts. The Pharmaceutical Division (Norwegian abbreviation: LIS) has previously published and held an open tender contest for non-parenteral special pharmaceutical preparations ('LIS 2201b non-parenteral special pharmaceutical preparations').
The contest was for the delivery of active ingredients in accordance with the tender documentation, annex 3 price sheet. Following the implementation of the tender contest, tenders have been made for Vimpat tablets and mixture (ATC code N03AX18). We received no other tenders for the relevant ATC code included in the tender contest. Based on this, the Pharmaceutical Division (Norwegian abbreviation: LIS) intends to enter into contracts between the regional health trusts (the Contracting Authorities) and UCB Pharma AS (the Supplier) as an supplementary agreement to LIS 2201b. I.e., the scope and length of the agreement shall follow the mentioned procurement (including access to extensions and terminations), without a new contest being held for this ingredient.
The health companies that are under the regional health trusts have an option to enter into the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region. LIS has explored the market situation and is of the opinion that it is impossible to carry out a new invitation to tender, or that a supplier other than UCB Pharma AS can deliver the product in the impending contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. LIS therefore believes that there are grounds to carry out the procurement without a tender contest. Cf. the Public Procurement Regulations §13-4, letter b, no. 3. LIS requests that those who have objections to the intended contract award submit feedback before the waiting period expires on 14.11.2021. If no objections are received, contracts will be signed after the waiting period has expired


Winner: UCB Pharma AS
Award value: 200000